智通财经网·2026-01-07 03:12Core Viewpoint - CanSino Biologics (06185) has seen a nearly 6% increase in stock price, currently trading at 38.8 HKD, following the announcement of the approval for clinical trials of its 24-valent pneumococcal polysaccharide conjugate vaccine (PCV24) by the National Medical Products Administration of China [1] Group 1: Product Development - The PCV24 vaccine has received approval to conduct clinical trials, marking a significant milestone for the company [1] - This vaccine is designed to cover 24 serotypes of pneumococcus, which are the main strains causing infectious diseases [1] - The development of PCV24 includes the production process and formulation confirmation of purified polysaccharides and polysaccharide-protein conjugates [1] Group 2: Market Position - As of the announcement date, there are no 24-valent pneumococcal conjugate vaccines available in the domestic and international markets [1] - The approval enhances the company's research pipeline in the pneumococcal conjugate vaccine sector, building on its existing technological foundation [1]